Pulse Biosciences Reports Six-Month PRECISE-BTN Study Results
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for benign thyroid nodules. The trial demonstrated that 86% of patients achieved the primary endpoint of at least a 50% nodule volume reduction, with a median reduction of 72%. Significant volume shrinkage was observed by one month and continued progressing without reported serious adverse events. Utilizing the company’s proprietary Nanosecond Pulsed Field Ablation (nano-PFA) technology, these findings were presented at the American Thyroid Association Annual Meeting, highlighting the system’s clinical potential.
Pulse Biosciences, Inc. (PLSE) announced six-month interim results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules.
According to the interim findings, 86% of patients achieved the study’s primary endpoint of at least a 50% reduction in nodule volume at six months. The median volume reduction was 72% at six months.
The majority of the volume reduction was evident by the one-month visit and continued to improve over time. No serious adverse events were reported.
Pulse Biosciences presented the results at the American Thyroid Association Annual Meeting. The system uses the company’s Nanosecond Pulsed Field Ablation™ technology, also known as nano-PFA or nsPFA™.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.